High-grade ovarian serous carcinoma exhibits significantly higher p16 expression than low-grade serous carcinoma and serous borderline tumour

Histopathology

Volumn 50, Issue 6, 2007, Pages 773-779

  O'Neill, C J ^a   McBride, H A ^a   Connolly, L E ^a   Deavers, M T ^b   Malpica, A ^b   McCluggage, W G ^a  

^a ROYAL GROUP OF HOSPITALS TRUST   (United Kingdom)

^b UNIVERSITY OF TEXAS   (United States)

Author keywords

High grade; Immunohistochemistry; Low grade; Ovary; p16; Serous carcinoma

Indexed keywords

MONOCLONAL ANTIBODY; PROTEIN P16INK4A;

ARTICLE; CARCINOGENESIS; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; OVARY CARCINOMA; PRECANCER; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; SCORING SYSTEM; STATISTICAL SIGNIFICANCE; TUMOR CELL;

CYCLIN-DEPENDENT KINASE INHIBITOR P16; DISEASE PROGRESSION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; NEOPLASM STAGING; NEOPLASMS, CYSTIC, MUCINOUS, AND SEROUS; OVARIAN NEOPLASMS; OVARY; PROGNOSIS; SEVERITY OF ILLNESS INDEX;

EID: 34247551305     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/j.1365-2559.2007.02682.x     Document Type: Article

References (47)

1. Shih IM, Kurman RJ. Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis. Am. J. Pathol. 2004 164 1511 1518.
2. Tucker Burks R, Sherman ME, Kurman RJ. Micropapillary serous carcinoma of the ovary: a distinctive low-grade carcinoma related to serous borderline tumors. Am. J. Surg. Pathol. 1996 20 1319 1330.
3. Russell HE, McCluggage WG. A multistep model for ovarian tumorigenesis: the value of mutation analysis in the KRAS and BRAF genes. JPathol. 2004 203 617 619.
4. Singer G, Stohr R, Cope L et al. Patterns of p53 mutations separate ovarian serous borderline tumors and low and high-grade carcinomas and provide support for a new model of ovarian carcinogenesis: a mutational analysis with immunohistochemical correlation. Am. J. Surg. Pathol. 2005 29 218 224.
5. Sieben NLG, Macropoulos R, Roemen GMJM et al. In ovarian neoplasms, BRAF, but not KRAS, mutation are restricted to low-grade serous tumors. JPathol. 2004 202 336 340.
6. Singer G, Kurman RJ, Chang HW et al. Diverse tumorigenic pathways in ovarian serous carcinoma. Am. J. Pathol. 2002 160 1223 1228.
7. Singer G, Shih IM, Truskinovsky A et al. Mutational analysis of K-ras segregates ovarian serous carcinomas into two types: invasive MPSC (low-grade tumor) and conventional serous carcinoma. Int. J. Gynecol. Pathol. 2003 22 37 41.
8. O'Neill CJ, Deavers MT, Malpica A et al. An immunohistochemical comparison between low-grade and high-grade ovarian serous carcinomas. Significantly higher expression of p53, MIB1, BCL2, HER-2/neu and C-KIT in high-grade neoplasms. Am. J. Surg. Pathol. 2005 29 1034 1041.
9. Ansari-Lari MA, Staebler A, Zaino RJ et al. BM. Distinction of endocervical and endometrial adenocarcinomas: immunohistochemical p16 expression correlated with human papillomavirus (HPV) DNA detection. Am. J. Surg. Pathol. 2004 28 160 167.
10. Armes JE, Lourie R, de Silva M et al. Abnormalities of the Rb1 pathway in ovarian serous papillary carcinoma as determined by overexpression of the p16 (INK4a) protein. Int. J. Gynecol. Pathol. 2005 24 363 368.
11. Malpica A, Deavers MT, Lu K et al. Grading ovarian serous carcinoma using a two-tier system. Am. J. Surg. Pathol. 2004 28 496 504.
12. Malpica A, Deavers MT, Tornos C et al. Interobserver variability of the two-tier system for grading ovarian serous carcinoma. Mod. Pathol. 2005 14 194A.
13. Ho C-L, Kurman RJ, Dehari R et al. Mutations of BRAF and KRAS precede the development of ovarian serous borderline tumors. Cancer Res. 2004 64 6915 6918.
14. Feeley FM, Wells M. Precursor lesions of ovarian epithelial malignancy. Histopathology 2001 32 87 95.
15. Nielsen GP, Stemmer-Rachamimov AO, Shaw J et al. Immunohistochemical survey of p16INK4A expression in normal human adult and infant tissues. Lab. Invest. 1999 79 1137 1143.
16. Sano T, Oyama T, Kashiwabara K et al. Immunohistochemical overexpression of p16 protein associated with intact retinoblastoma protein expression in cervical cancer and cervical intraepithelial neoplasia. Pathol. Int. 1998 48 580 585.
17. O'Neill CJ, McCluggage WG. p16 expression in the female genital tract and its value in diagnosis. Adv. Anat. Pathol. 2006 13 8 15.
18. Sano T, Oyama T, Kashiwabara K et al. Expression status of p16 protein is associated with human papillomavirus oncogenic potential in cervical and genital lesions. Am. J. Pathol. 1998 153 1741 1748.
19. Klaes R, Friedrich T, Spitkovsky D et al. Overexpression of p16INK4a as a specific marker for dysplastic and neoplastic epithelial cells of the cervix uteri. Int. J. Cancer 2001 92 276 284.
20. Keating JT, Cviko A, Reithdorf S et al. Ki-67, cyclin E and p16 are complimentary surrogate biomarkers for human papillomavirus-related cervical neoplasia. Am. J. Surg. Pathol. 2001 25 894 991.
21. Milde-Langosch K, Reithdorf S, Kraws-Poppinghaus A. Expression of cyclin-dependent kinase inhibitors p16, p21 and p27 in HPV-positive and HPV-negative cervical adenocarcinomas. Virchows Arch. 2001 439 55 61.
22. Kalof AN, Evans MF, Simmons-Arnold L et al. p16 INK4A immunoexpression and HPV in situ hybridization signal patterns: potential markers of high-grade cervical intraepithelial neoplasia. Am. J. Surg. Pathol. 2005 29 674 679.
23. Hu L, Guo M, He Z et al. Human papillomavirus genotyping and p16INK4a expression in cervical intraepithelial neoplasia of adolescents. Mod. Pathol. 2005 18 267 273.
24. Tringler B, Gup CJ, Singh M et al. Evaluation of p16INK4a and pRb expression in cervical squamous and glandular neoplasia. Hum. Pathol. 2004 35 689 696.
25. Dray M, Russell P, Dulrymple C et al. p16 (INK4a) as a complementary marker of high-grade intraepithelial lesions of the uterine cervix. I. Experience with squamous lesions in 189 consecutive cervical biopsies. Pathology 2005 37 112 124.
26. Agoff SN, Lin P, Morihara J et al. p16 (INK4a) expression correlates with degree of cervical neoplasia: a comparison with Ki67 expression and detection of high-risk HPV types. Mod. Pathol. 2003 16 665 673.
27. Negri G, Vittadello F, Romano F et al. p16INK4a expression and progression risk of low-grade intraepithelial neoplasia of the cervix uteri. Virchows Arch. 2004 445 616 620.
28. Guimaraes MC, Goncalves MA, Soares P et al. Immunohistochemical expression of p16INK4a and bcl-2 acording to HPV type and to the progression of cervical squamous intraepithelial lesions. JHistochem. Cytochem. 2005 53 509 516.
29. Aoyama C, Liu P, Ostrzega N et al. Histologic and immunohistochemical characteristics of neoplastic and nonneoplastic subgroups of atypical squamous lesions of the uterine cervix. Am. J. Clin. Pathol. 2005 123 699 705.
30. Klaes R, Benner A, Friedrich T et al. p16 INK 4a immunohistochemistry improves interobserver agreement in the diagnosis of cervical intraepithelial neoplasia. Am. J. Surg. Pathol. 2002 26 1389 1399.
31. Qiao X, Bhuiya TA, Spitzer M. Differentiating high-grade cervical intraepithelial lesion from atrophy in postmenopausal women using Ki-67, cyclin E and p16 immunohistochemical analysis. JLow Genit. Tract Dis. 2005 9 100 107.
32. Cameron RI, Maxwell P, Jenkins D et al. Immunohistochemical staining with MIB1, bcl2 and p16 assists in the distinction of cervical glandular intraepithelial neoplasia from tubo-endometrial metaplasia, endometriosis and microglandular hyperplasia. Histopathology 2002 41 313 321.
33. Zielinski GD, Snijders PJ, Rozendaal L et al. The presence of high-risk HPV combined with specific p53 and p16 INK 4A expression patterns points to high-risk HPV as the main causative agent for adenocarcinoma in situ and adenocarcinoma of the cervix. JPathol. 2003 201 535 543.
34. Negri G, Egarter-Vigl E, Kasal A et al. p16 INK4a is a useful marker for the diagnosis of adenocarcinoma of the cervix uteri and its precursors: an immunohistochemical study with immunocytochemical correlations. Am. J. Surg. Pathol. 2003 27 187 193.
35. Murphy N, Heffron CC, Ling B et al. p16INK4a positivity in benign, premalignant and malignant cervical glandular lesions: a potential diagnostic problem. Virchows Arch. 2004 445 610 615.
36. Riethdorf L, Riethdorf S, Lee KR et al. Human papillomaviruses, expression of p16 and early endocervical glandular neoplasia. Hum. Pathol. 2002 33 899 904.
37. Dong Y, Walsh MD, McGuckin MA et al. Increased expression of cyclin-dependent kinase inhibitor 2 (CDKN2A) gene product p16INK4A in ovarian cancer is associated with progression and unfavourable prognosis. Int. J. Cancer 1997 74 57 63.
38. Vang R, Gown AM, Barry TS et al. p16 expression in primary ovarian mucinous and endometrioid tumours and metastatic adenocarcinomas in the ovary: utility for identification of metastatic HPV-related endocervical adenocarcinomas. Mod. Pathol. 2006 19 200A.
39. Elishaev E, Gilks CB, Miller D et al. Synchronous and metachronous endocervical and ovarian neoplasms: evidence supporting interpretation of the ovarian neoplasms as metastatic endocervical adenocarcinomas simulating primary ovarian surface epithelial neoplasms. Am. J. Surg. Pathol. 2005 29 281 294.
40. McCluggage WG, Jenkins D. Immunohistochemical staining with p16 may assist in the distinction between endometrial and endocervical adenocarcinoma. Int. J. Gynecol. Pathol. 2003 22 231 235.
41. Anttila M, Syrjanen S, Ji H et al. Failure to demonstrate human papilloma virus DNA in epithelial ovarian cancer by general primer PCR. Gynecol. Oncol. 1999 72 337 341.
42. Yemelyanova H, Ji H, Ronnett BM. Diffuse p16 expression distinguishes uterine serous carcinoma (USC) from uterine endometrioid carcinoma of endometrial origin (UEC) but not HPV-related endocervical adenocarcinoma (ECC). Mod. Pathol. 2006 19 202A.
43. Hashi A, Yuminamochi T, Murata SI et al. Wilms tumor gene immunoreactivity in primary serous carcinomas of the fallopian tube, ovary, endometrium and peritoneum. Int. J. Gynecol. Pathol. 2004 22 374 377.
44. Goldstein NS, Uzieblo A. WTI immunoreactivity in uterine papillary serous carcinomas is different from ovarian serous carcinomas. Am. J. Clin. Pathol. 2002 117 541 545.
45. Hwang H, Quenneville L, Yaziji H et al. Wilms tumor gene product: sensitive and contextually specific marker of serous carcinomas of ovarian surface epithelial origin. Appl. Immunohistochem. Mol. Morphol. 2004 12 122 126.
46. McCluggage WG. WT1 is of value in ascertaining the site of origin of serous carcinomas within the female genital tract. Int. J. Gynecol. Pathol. 2004 23 97 99.
47. Shimizu M, Toki T, Takagi Y et al. Immunohistochemical detection of the Wilm's tumor gene (WT1) in epithelial ovarian tumors. Int. J. Gynecol. Pathol. 2000 19 158 163.